<DOC>
	<DOCNO>NCT02660281</DOCNO>
	<brief_summary>This study single-center treatment protocol , design validate process relate donor haploidentical-SCT Wilmot Cancer Institute Blood Marrow Transplant Unit .</brief_summary>
	<brief_title>URMC Related Haplo-identical Donor BMT</brief_title>
	<detailed_description>This study single-center treatment protocol four possible preparative regimen , design validate process relate donor haploidentical-SCT Wilmot Cancer Institute Blood Marrow Transplant Unit . Enrolled patient receive chemotherapy +/- radiation pre-transplant conditioning regimen . Patients receive haploidentical stem cell , either bone marrow mobilize peripheral blood , follow GvHD prophylaxis include cyclophosphamide . Multiple data point collect prior , , follow transplantation ensure safety process evaluate state objective .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Patient Age : Pediatric ( age 6 month 18 year ) Adult ( age 1875 year ) Disease : Congenital Other Nonmalignant Disorders Immunodeficiency disorder ( e.g . Severe Combined Immunodeficiency , WiskottAldrich Syndrome ) Congenital hematopoietic stem cell defect ( e.g . ChediakHigashi Syndrome , Congenital Osteopetrosis , Osteogenesis Imperfecta ) Metabolic disorder ( e.g . Hurler 's Syndrome ) Hemoglobinopathies ( e.g . Sickle Cell Disease , Thalassemia ) Severe aplastic anemia HighRisk Leukemias Acute Myelogenous Leukemia Refractory standard induction therapy ( 1 cycle require achieve remission ) Recurrent ( CR≥2 ) Treatmentrelated AML MDS Evolved myelodysplastic syndrome Presence Flt3 abnormalities FAB M6 M7 Adverse cytogenetics Myelodysplastic Syndrome Acute Lymphoblastic Leukemia include T lymphoblastic leukemia Refractory standard induction therapy ( time CR &gt; 4 week ) Recurrent ( CR ≥2 ) WBC count &gt; 30,000/mcL diagnosis Age &gt; 30 diagnosis Adverse cytogenetics , ( ( 9:22 ) , ( 1:19 ) , ( 4:11 ) , MLL rearrangement . Chronic Myelogenous Leukemia accelerate phase blast crisis Biphenotypic undifferentiated leukemia Burkitt 's leukemia lymphoma Lymphoma : Large cell , Mantle cell , Hodgkin lymphoma refractory recurrent , chemosensitive , ineligible autologous stem cell transplant previously treat autologous SCT Marginal zone follicular lymphoma progressive least two prior therapy Multiple Myeloma , recurrent follow highdose therapy autologous SCT ineligible autologous HSCT Solid tumor , efficacy allogeneic HSCT demonstrate specific disease disease status Graft failure follow prior relate donor , unrelated donor UCB transplant Myelofibrosis 1 . Patient Age 6 month 75 year 2 . Availability 10/10 HLAmatched relate unrelated donor within reasonable timeframe dictate clinical urgency transplant 3 . Autologous HSCT &lt; 6 month prior propose haploSCT 4 . Pregnant breastfeed 5 . Current uncontrolled infection 6 . Evidence HIV infection positive HIV serology 7 . Antidonor HLA antibody positive crossmatch unsuccessful</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>